Gilead's Trop-2 Targeting ADC, Trodelvy, Receives EMA Approval for Metastatic Triple-Negative Breast Cancer in Europe
A Paradigm Shift in Triple-Negative Breast Cancer Treatment
Gilead Sciences' antibody-drug conjugate (ADC), Trodelvy (sacituzumab govitecan), has received final marketing authorization from the European Medicines Agency (EMA). This approval is for adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies. Triple-negative breast cancer is an aggressive disease with limited targeted therapy options, making this regulatory approval a significant therapeutic advancement for patients. Based on superior clinical data compared to standard chemotherapy, Trodelvy has demonstrated efficacy and opened the door to the European market.
Survival Benefits Demonstrated in Phase 3 ASCENT Study
The basis for this European approval is the positive data from the Phase 3 ASCENT clinical trial. The study results showed that the Trodelvy arm significantly extended median progression-free survival (PFS) from 1.7 months to 4.8 months compared to the treatment of physician's choice (TPC) arm, reducing the risk of disease progression or death by 59% (Hazard Ratio 0.41). Furthermore, median overall survival (OS) was also significantly improved, from 6.9 months in the control group to 11.8 months, reducing the risk of death by 49% (Hazard Ratio 0.51). This robust clinical data has maximized the drug's credibility and played a crucial role in the EMA's rapid approval decision.
Gilead's $21 Billion Acquisition Validated
Trodelvy was originally developed by Immunomedics, and Gilead acquired the company in 2020 for $21 billion. At the time, some market analysts expressed concerns about the high price, but this European approval strongly validates the asset's commercial value and strategic decision. Trodelvy targets the Trop-2 (Trophoblast Cell-Surface Antigen 2) protein on the surface of cells, delivering the potent anticancer drug SN-38 directly into the cells. This technology further confirms the superiority of the next-generation ADC platform and establishes Trodelvy as a key driver of Gilead's oncology pipeline.
The Competitive Landscape in the Global Breast Cancer Treatment Market
The market for metastatic triple-negative breast cancer and HER2-low breast cancer is currently highly competitive, with AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) leading the way. Additionally, Datopotamab Deruxtecan (Dato-DXd), a competing Trop-2 targeting ADC, is also accelerating its clinical development, intensifying the race for market share. Trodelvy has achieved strong commercial growth, exceeding $1.4 billion in global annual sales in 2025. However, to expand its market share, it is crucial to diversify its clinical development, including Phase 3 trials to expand its target patient population to first-line treatment or other solid tumors. This European approval will undoubtedly serve as a solid commercial foundation for increasing global sales and securing market share.
The European EMA final approval of Trodelvy represents a pivotal milestone in the treatment of metastatic triple-negative breast cancer (mTNBC), a disease with high unmet medical needs. Based on Phase 3 clinical data demonstrating a 49% reduction in the risk of death compared to standard chemotherapy, Trodelvy is poised to revolutionize the treatment paradigm. Gilead's $21 billion acquisition of Immunomedics in 2020 has proven to be a successful investment, with Trodelvy achieving $1.4 billion in global annual sales in 2025 and expected to drive over $1 billion in additional European market share. In the face of intense competition from AstraZeneca and Daiichi Sankyo's Enhertu, and the emerging Trop-2 targeting ADC, Datopotamab Deruxtecan (Dato-DXd), Trodelvy's early entry into the European market will be a critical factor in maintaining long-term market dominance. From a research perspective, the success of ongoing Phase 3 trials in triple-negative breast cancer, hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer, and other solid tumors will be key indicators of long-term expansion and corporate value.
Source: EMA (ema)